{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:08:14Z","timestamp":1789204094668,"version":"build-2803163510"},"reference-count":120,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"unspecified","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project","award":["2026ZD01912401"],"award-info":[{"award-number":["2026ZD01912401"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["egastro"],"accepted":{"date-parts":[[2026,8,7]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease characterised by immune-mediated destruction of small intrahepatic bile ducts. Although ursodeoxycholic acid remains the standard first-line therapy and peroxisome proliferator-activated receptor agonists have expanded treatment options, current therapies do not fully address the immune mechanisms that drive disease initiation and persistence. Recent work suggests that PBC cannot be explained by abnormalities in a single immune-cell population but instead reflects coordinated immune remodelling around injured bile ducts. In this review, we organise current evidence within an overlapping, process-oriented framework encompassing immune initiation, effector amplification and immune-regulatory dysfunction. Stressed biliary epithelial cells provide autoantigens, immune-sensing signals and inflammatory cues while myeloid cells and lymphocyte subsets cooperate to sustain tissue-resident cytotoxic, inflammatory and profibrogenic circuits. Disease chronicity is further promoted by defective regulatory mechanisms, including impaired Treg stability and dysfunction of non-conventional regulatory populations. We also discuss mechanism-guided therapeutic strategies targeting effector T cells, myeloid inflammation, B-cell activation, immune tolerance and the cholestatic microenvironment. Understanding the peribiliary immune niche may facilitate immune phenotype-guided stratification and precision therapy in PBC.<\/jats:p>","DOI":"10.1136\/egastro-2026-100526","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:30:24Z","timestamp":1789201824000},"page":"e100526","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Immune cell remodelling and the peribiliary immune niche in primary biliary cholangitis: from initiation to chronicity"],"prefix":"10.1136","volume":"4","author":[{"given":"Jiaqi","family":"Xiong","sequence":"first","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, Beijing, China"},{"name":"Medical School of Chinese PLA, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, Beijing, China"},{"name":"Medical School of Chinese PLA, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, Beijing, China"},{"name":"302 Clinical Medical School, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Yuan","sequence":"additional","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, Beijing, China"},{"name":"302 Clinical Medical School, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaidi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, Beijing, China"},{"name":"Medical School of Chinese PLA, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8043-6685","authenticated-orcid":false,"given":"Fu-Sheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, Beijing, China"},{"name":"Medical School of Chinese PLA, Beijing, China"},{"name":"302 Clinical Medical School, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5727-3590","authenticated-orcid":false,"given":"Lei","family":"Shi","sequence":"additional","affiliation":[{"name":"Senior Department of Infectious Diseases, Chinese PLA General Hospital, Beijing, China"},{"name":"Medical School of Chinese PLA, Beijing, China"},{"name":"302 Clinical Medical School, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"2026091201301767000_4.3.e100526.1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2025.03.025","article-title":"Global Epidemiology of Primary Biliary Cholangitis: An Updated Systematic Review and Meta-Analysis","volume":"24","author":"Tan","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026091201301767000_4.3.e100526.2","doi-asserted-by":"crossref","first-page":"111754","DOI":"10.1016\/j.biopha.2021.111754","article-title":"The pathogenesis, models and therapeutic advances of primary biliary cholangitis","volume":"140","author":"Li","year":"2021","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"2026091201301767000_4.3.e100526.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.04.055"},{"key":"2026091201301767000_4.3.e100526.4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJMe2312745","article-title":"Advancing Second-Line Treatment for Primary Biliary Cholangitis","volume":"390","author":"Assis","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091201301767000_4.3.e100526.5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","article-title":"Primary biliary cholangitis","volume":"404","author":"Tanaka","year":"2024","journal-title":"The Lancet"},{"key":"2026091201301767000_4.3.e100526.6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ueg2.12095","article-title":"Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease","volume":"9","author":"Cortez-Pinto","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"2026091201301767000_4.3.e100526.7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2468-1253(19)30343-7","article-title":"Current and potential treatments for primary biliary cholangitis","volume":"5","author":"Shah","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026091201301767000_4.3.e100526.8","first-page":"49","article-title":"Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches","volume":"8","author":"Galoosian","year":"2020","journal-title":"J Clin Transl Hepatol"},{"key":"2026091201301767000_4.3.e100526.9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091201301767000_4.3.e100526.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102619"},{"key":"2026091201301767000_4.3.e100526.11","doi-asserted-by":"crossref","unstructured":"Jin C , Jiang P , Zhang Z , et al . Single-cell RNA sequencing reveals the pro-inflammatory roles of liver-resident Th1-like cells in primary biliary cholangitis. Nat Commun 2024;15:8690. doi:10.1038\/s41467-024-53104-9","DOI":"10.1038\/s41467-024-53104-9"},{"key":"2026091201301767000_4.3.e100526.12","doi-asserted-by":"crossref","unstructured":"Yang Y , He X , Rojas M , et al . Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis? Front Immunol 2023;14:1184252. doi:10.3389\/fimmu.2023.1184252","DOI":"10.3389\/fimmu.2023.1184252"},{"key":"2026091201301767000_4.3.e100526.13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.09.004"},{"key":"2026091201301767000_4.3.e100526.14","unstructured":"Wang Q , Gan M . Pathological diagnosis of primary biliary cholangitis. J Clin Hepatol 2024;40. doi:10.12449\/JCH240604"},{"key":"2026091201301767000_4.3.e100526.15","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jhep.2014.11.027","article-title":"Autophagy and senescence in fibrosing cholangiopathies","volume":"62","author":"Nakanuma","year":"2015","journal-title":"J Hepatol"},{"key":"2026091201301767000_4.3.e100526.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.03.008"},{"key":"2026091201301767000_4.3.e100526.17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22348"},{"key":"2026091201301767000_4.3.e100526.18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1383727"},{"key":"2026091201301767000_4.3.e100526.19","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.5mr0320-200r"},{"key":"2026091201301767000_4.3.e100526.20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27840"},{"key":"2026091201301767000_4.3.e100526.21","doi-asserted-by":"crossref","unstructured":"Chen R , Sun Y , Hu Y , et al . Innate immunity of bile and cholangiocytes in primary biliary cholangitis. Front Immunol 2025;16:1655287. doi:10.3389\/fimmu.2025.1655287","DOI":"10.3389\/fimmu.2025.1655287"},{"key":"2026091201301767000_4.3.e100526.22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: pathogenesis and therapeutic opportunities","volume":"17","author":"Gulamhusein","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026091201301767000_4.3.e100526.23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22102"},{"key":"2026091201301767000_4.3.e100526.24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22011"},{"key":"2026091201301767000_4.3.e100526.25","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/HEP.0000000000001093","article-title":"Central role for cholangiocyte pathobiology in cholestatic liver diseases","volume":"82","author":"Jalan-Sakrikar","year":"2025","journal-title":"Hepatology"},{"key":"2026091201301767000_4.3.e100526.26","doi-asserted-by":"crossref","first-page":"103376","DOI":"10.1016\/j.jaut.2025.103376","article-title":"Immunobiology of bile and cholangiocytes","volume":"151","author":"Li","year":"2025","journal-title":"J Autoimmun"},{"key":"2026091201301767000_4.3.e100526.27","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2024-100074","article-title":"Bile acids regulation of cellular stress responses in liver physiology and diseases","volume":"2","author":"Li","year":"2024","journal-title":"egastroenterology"},{"key":"2026091201301767000_4.3.e100526.28","doi-asserted-by":"crossref","unstructured":"Sasaki M , Sato Y , Nakanuma Y . Interferon-induced protein with tetratricopeptide repeats 3 may be a key factor in primary biliary cholangitis. Sci Rep 2021;11:11413. doi:10.1038\/s41598-021-91016-6","DOI":"10.1038\/s41598-021-91016-6"},{"key":"2026091201301767000_4.3.e100526.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.06.025"},{"key":"2026091201301767000_4.3.e100526.30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0344-0338(99)80028-4","article-title":"Immunohistochemical Localization of Antigen Presenting Cells in Liver from Patients with Primary Biliary Cirrhosis; Highly Restricted Distribution of CD83-positive Activated Dendritic Cells","volume":"195","author":"Tanimoto","year":"1999","journal-title":"Pathology - Research and Practice"},{"key":"2026091201301767000_4.3.e100526.31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/cmi.2015.86","article-title":"The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis","volume":"14","author":"Tomiyama","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"2026091201301767000_4.3.e100526.32","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/liv.15961","article-title":"Conventional type 1 dendritic cells are essential for the development of primary biliary cholangitis","volume":"44","author":"Reuveni","year":"2024","journal-title":"Liver Int"},{"key":"2026091201301767000_4.3.e100526.33","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH725>3.0.CO;2-P"},{"key":"2026091201301767000_4.3.e100526.34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01852","article-title":"The Critical Role of Chemokine (C-C Motif) Receptor 2-Positive Monocytes in Autoimmune Cholangitis","volume":"9","author":"Reuveni","year":"2018","journal-title":"Front Immunol"},{"key":"2026091201301767000_4.3.e100526.35","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23783"},{"key":"2026091201301767000_4.3.e100526.36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.718841","article-title":"Interleukin 23 Produced by Hepatic Monocyte-Derived Macrophages Is Essential for the Development of Murine Primary Biliary Cholangitis","volume":"12","author":"Reuveni","year":"2021","journal-title":"Front Immunol"},{"key":"2026091201301767000_4.3.e100526.37","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70525","article-title":"IGFBP4 is a Metric for Primary Biliary Cholangitis and Attenuates Biliary Epithelial Cell Injury","volume":"46","author":"Zhou","year":"2026","journal-title":"Liver Int"},{"key":"2026091201301767000_4.3.e100526.38","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-335611"},{"key":"2026091201301767000_4.3.e100526.39","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24526"},{"key":"2026091201301767000_4.3.e100526.40","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jhep.2022.06.014","article-title":"NUDT1 promotes the accumulation and longevity of CD103+ TRM cells in primary biliary cholangitis","volume":"77","author":"Huang","year":"2022","journal-title":"J Hepatol"},{"key":"2026091201301767000_4.3.e100526.41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-44910-2","article-title":"Expression of E-cadherin by CD8+ T cells promotes their invasion into biliary epithelial cells","volume":"15","author":"Davies","year":"2024","journal-title":"Nat Commun"},{"key":"2026091201301767000_4.3.e100526.42","doi-asserted-by":"crossref","first-page":"102293","DOI":"10.1016\/j.jaut.2019.06.004","article-title":"Cytotoxic KLRG1 expressing lymphocytes invade portal tracts in primary biliary cholangitis","volume":"103","author":"Li","year":"2019","journal-title":"J Autoimmun"},{"key":"2026091201301767000_4.3.e100526.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.12.012"},{"key":"2026091201301767000_4.3.e100526.44","doi-asserted-by":"crossref","unstructured":"Long J , Yang SY , Bian ZH , et al . PD\u20101+CD8+ T Cell\u2010Mediated Hepatocyte Pyroptosis Promotes Progression of Murine Autoimmune Liver Disease. Advanced Science 2025;12:2407284. doi:10.1002\/advs.202407284","DOI":"10.1002\/advs.202407284"},{"key":"2026091201301767000_4.3.e100526.45","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/cmi.2017.149","article-title":"Proteomic analysis reveals distinctive protein profiles involved in CD8+ T cell-mediated murine autoimmune cholangitis","volume":"15","author":"Zhang","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"2026091201301767000_4.3.e100526.46","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-015-0381-2"},{"key":"2026091201301767000_4.3.e100526.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.08.004"},{"key":"2026091201301767000_4.3.e100526.48","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27725"},{"key":"2026091201301767000_4.3.e100526.49","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27306"},{"key":"2026091201301767000_4.3.e100526.50","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/hep4.1226","article-title":"Follicular T Helper Cell Signatures in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis","volume":"2","author":"Adam","year":"2018","journal-title":"Hepatol Commun"},{"key":"2026091201301767000_4.3.e100526.51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2025.100314","article-title":"Cell-specific epigenome-wide DNA methylation in peripheral CD4(+) lymphocytes from patients with primary biliary cholangitis","volume":"11","author":"Arvaniti","year":"2025","journal-title":"J Transl Autoimmun"},{"key":"2026091201301767000_4.3.e100526.52","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27313"},{"key":"2026091201301767000_4.3.e100526.53","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/liv.13554","article-title":"Clonal characteristics of paired infiltrating and circulating B lymphocyte repertoire in patients with primary biliary cholangitis","volume":"38","author":"Tan","year":"2018","journal-title":"Liver International"},{"key":"2026091201301767000_4.3.e100526.54","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1688751"},{"key":"2026091201301767000_4.3.e100526.55","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jhep.2025.06.037","article-title":"B cells drive CCR5+CD4+ tissue-resident memory T-cell cytotoxicity via IL-15R\u03b1-IL-15 signaling in primary biliary cholangitis","volume":"83","author":"Pu","year":"2025","journal-title":"J Hepatol"},{"key":"2026091201301767000_4.3.e100526.56","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29782"},{"key":"2026091201301767000_4.3.e100526.57","doi-asserted-by":"crossref","first-page":"103442","DOI":"10.1016\/j.jaut.2025.103442","article-title":"The phenotypic and functional characteristics of intrahepatic CD69+CD103+ tissue-resident MAIT cells in primary biliary cholangitis","volume":"154","author":"Xia","year":"2025","journal-title":"J Autoimmun"},{"key":"2026091201301767000_4.3.e100526.58","doi-asserted-by":"crossref","unstructured":"Zhu B , Zhang C , Ma J , et al . Molecular mechanisms underlying T cell subset imbalance and precision therapeutic targets in primary biliary cholangitis. Front Pharmacol 2026;17:1769883. doi:10.3389\/fphar.2026.1769883","DOI":"10.3389\/fphar.2026.1769883"},{"key":"2026091201301767000_4.3.e100526.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.01.007"},{"key":"2026091201301767000_4.3.e100526.60","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24194"},{"key":"2026091201301767000_4.3.e100526.61","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jhep.2020.08.024","article-title":"A spotlight on natural killer cells in primary biliary cholangitis","volume":"74","author":"Hydes","year":"2021","journal-title":"J Hepatol"},{"key":"2026091201301767000_4.3.e100526.62","doi-asserted-by":"crossref","first-page":"103454","DOI":"10.1016\/j.jaut.2025.103454","article-title":"A novel subset of inflammation-related liver NK cells modulates immune responses in a murine model of primary biliary cholangitis","volume":"155","author":"Da","year":"2025","journal-title":"J Autoimmun"},{"key":"2026091201301767000_4.3.e100526.63","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/JLB.2A0622-586RRRR","article-title":"IL-17A produced by invariant natural killer T cells and CD3+CD56+\u03b1Galcer-CD1d tetramer\u2013 T cells promote liver fibrosis in patients with primary biliary cholangitis","volume":"112","author":"Jia","year":"2022","journal-title":"J Leukoc Biol"},{"key":"2026091201301767000_4.3.e100526.64","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae973"},{"key":"2026091201301767000_4.3.e100526.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2010.06.004"},{"key":"2026091201301767000_4.3.e100526.66","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/cmi.2010.40","article-title":"CD4+CD25+ but not CD4+Foxp3+ T cells as a regulatory subset in primary biliary cirrhosis","volume":"7","author":"Wang","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"2026091201301767000_4.3.e100526.67","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaut.2018.07.020","article-title":"Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN-\u03b3 secreting cells","volume":"94","author":"Liaskou","year":"2018","journal-title":"J Autoimmun"},{"key":"2026091201301767000_4.3.e100526.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.01.011"},{"key":"2026091201301767000_4.3.e100526.69","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/hep.29418","article-title":"A functional characteristic of cysteine\u2010rich protein 61: Modulation of myeloid\u2010derived suppressor cells in liver inflammation","volume":"67","author":"Zhang","year":"2018","journal-title":"Hepatology"},{"key":"2026091201301767000_4.3.e100526.70","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.05.014"},{"key":"2026091201301767000_4.3.e100526.71","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0199-z"},{"key":"2026091201301767000_4.3.e100526.72","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jhep.2010.07.018","article-title":"NK cells suppress experimental cholestatic liver injury by an interleukin-6-mediated, Kupffer cell-dependent mechanism","volume":"54","author":"Cheng","year":"2011","journal-title":"J Hepatol"},{"key":"2026091201301767000_4.3.e100526.73","doi-asserted-by":"crossref","unstructured":"Wu Z , Zheng Y , Sheng J , et al . CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer. Front Immunol 2022;13:816005. doi:10.3389\/fimmu.2022.816005","DOI":"10.3389\/fimmu.2022.816005"},{"key":"2026091201301767000_4.3.e100526.74","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/liv.14136","article-title":"Alteration of liver-infiltrated and peripheral blood double-negative T-cells in primary biliary cholangitis","volume":"39","author":"Li","year":"2019","journal-title":"Liver Int"},{"key":"2026091201301767000_4.3.e100526.75","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/hep.31724","article-title":"Enoxacin Up-Regulates MicroRNA Biogenesis and Down-Regulates Cytotoxic CD8 T-Cell Function in Autoimmune Cholangitis","volume":"74","author":"Itoh","year":"2021","journal-title":"Hepatology"},{"key":"2026091201301767000_4.3.e100526.76","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-022-00904-y"},{"key":"2026091201301767000_4.3.e100526.77","doi-asserted-by":"crossref","unstructured":"Zhu H-X , Yang S-H , Gao C-Y , et al . Targeting pathogenic CD8+ tissue-resident T cells with chimeric antigen receptor therapy in murine autoimmune cholangitis. Nat Commun 2024;15:2936. doi:10.1038\/s41467-024-46654-5","DOI":"10.1038\/s41467-024-46654-5"},{"key":"2026091201301767000_4.3.e100526.78","doi-asserted-by":"crossref","first-page":"107820","DOI":"10.1016\/j.intimp.2021.107820","article-title":"5-Aza-2-deoxycytidine alleviates the progression of primary biliary cholangitis by suppressing the FoxP3 methylation and promoting the Treg\/Th17 balance","volume":"96","author":"Jiang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2026091201301767000_4.3.e100526.79","doi-asserted-by":"crossref","first-page":"103327","DOI":"10.1016\/j.jaut.2024.103327","article-title":"Identification of a novel PDC-E2 epitope in primary biliary cholangitis: Application for engineered Treg therapy","volume":"149","author":"Tewari","year":"2024","journal-title":"J Autoimmun"},{"key":"2026091201301767000_4.3.e100526.80","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00281-022-00940-w","article-title":"Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease","volume":"44","author":"Richardson","year":"2022","journal-title":"Semin Immunopathol"},{"key":"2026091201301767000_4.3.e100526.81","doi-asserted-by":"crossref","unstructured":"Zhang C , Sun G , Jin H , et al . Double-negative T cells in combination with ursodeoxycholic acid ameliorates immune-mediated cholangitis in mice. BMC Med 2025;23:209. doi:10.1186\/s12916-025-04043-9","DOI":"10.1186\/s12916-025-04043-9"},{"key":"2026091201301767000_4.3.e100526.82","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28359"},{"key":"2026091201301767000_4.3.e100526.83","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29544"},{"key":"2026091201301767000_4.3.e100526.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2016.02.012"},{"key":"2026091201301767000_4.3.e100526.85","doi-asserted-by":"crossref","unstructured":"Wang Z , Gao W , Cheng X , et al . Vitamin D3 attenuates hepatic inflammation in primary biliary cholangitis by inhibiting TLR4\/NF-\u03baB mediated M1 macrophage polarization. Sci Rep 2025;15:44345. doi:10.1038\/s41598-025-27911-z","DOI":"10.1038\/s41598-025-27911-z"},{"key":"2026091201301767000_4.3.e100526.86","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.51"},{"key":"2026091201301767000_4.3.e100526.87","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/hep.30099","article-title":"Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial","volume":"70","author":"Khanna","year":"2019","journal-title":"Hepatology"},{"key":"2026091201301767000_4.3.e100526.88","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2023.100189","article-title":"Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis - a case series","volume":"6","author":"Kolev","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"2026091201301767000_4.3.e100526.89","doi-asserted-by":"crossref","unstructured":"Zhang W , Shao T , Leung PSC , et al . Dual B-cell targeting therapy ameliorates autoimmune cholangitis. J Autoimmun 2022;132:102897. doi:10.1016\/j.jaut.2022.102897","DOI":"10.1016\/j.jaut.2022.102897"},{"key":"2026091201301767000_4.3.e100526.90","unstructured":"U.S. Food and Drug Administration . Serious liver injury being observed in patients without cirrhosis taking ocaliva (obeticholic acid) to treat primary biliary cholangitis: FDA web site. 2024. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-communications\/serious-liver-injury-being-observed-patients-without-cirrhosis-taking-ocaliva-obeticholic-acid-treat [Accessed 4 Jun 2026]."},{"key":"2026091201301767000_4.3.e100526.91","unstructured":"Food and Drug Administration H . Intercept pharmaceuticals, inc., et al.; withdrawal of approval of new drug application for ocaliva (obeticholic acid) tablets, 5 milligrams and 10 milligrams, and three abbreviated new drug applications for obeticholic acid tablets, 5 milligrams and 10 milligrams. Available: https:\/\/www.federalregister.gov\/documents\/2025\/11\/24\/2025-20767\/intercept-pharmaceuticals-inc-et-al-withdrawal-of-approval-of-new-drug-application-for-ocaliva [accessed 4 Jun 2026]"},{"key":"2026091201301767000_4.3.e100526.92","doi-asserted-by":"crossref","DOI":"10.3390\/ph18091424","article-title":"Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders","volume":"18","author":"Fiorucci","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026091201301767000_4.3.e100526.93","doi-asserted-by":"crossref","first-page":"100544","DOI":"10.1016\/j.jhepr.2022.100544","article-title":"Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis","volume":"4","author":"Schramm","year":"2022","journal-title":"JHEP Reports"},{"key":"2026091201301767000_4.3.e100526.94","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-023-02653-2","article-title":"PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis","volume":"23","author":"Trauner","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"2026091201301767000_4.3.e100526.95","doi-asserted-by":"crossref","unstructured":"Gordon SC , Proehl S , Pratt D , et al . Seladelpar Improves Cholestasis and Pruritus in Obeticholic Acid and Fibrate-Experienced Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology 2026. doi:10.1016\/j.cgh.2026.01.011","DOI":"10.1016\/j.cgh.2026.01.011"},{"key":"2026091201301767000_4.3.e100526.96","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/HEP.0000000000000728","article-title":"Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis","volume":"80","author":"Kremer","year":"2024","journal-title":"Hepatology"},{"key":"2026091201301767000_4.3.e100526.97","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J Hepatol"},{"key":"2026091201301767000_4.3.e100526.98","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/MS9.0000000000002794","article-title":"Elafibranor: a breakthrough therapy revolutionizing primary biliary cholangitis (PBC) treatment","volume":"87","author":"Gul","year":"2025","journal-title":"Annals of Medicine & Surgery"},{"key":"2026091201301767000_4.3.e100526.99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306185"},{"key":"2026091201301767000_4.3.e100526.100","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/HEP.0000000000000395","article-title":"Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study","volume":"78","author":"Hirschfield","year":"2023","journal-title":"Hepatology"},{"key":"2026091201301767000_4.3.e100526.101","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/hepr.13361","article-title":"Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis","volume":"49","author":"Joshita","year":"2019","journal-title":"Hepatol Res"},{"key":"2026091201301767000_4.3.e100526.102","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/hepr.14172","article-title":"Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: Nationwide, multicenter study by the Japanese Red Cross Liver Study Group","volume":"55","author":"Tsuji","year":"2025","journal-title":"Hepatol Res"},{"key":"2026091201301767000_4.3.e100526.103","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis","volume":"76","author":"Vuppalanchi","year":"2022","journal-title":"J Hepatol"},{"key":"2026091201301767000_4.3.e100526.104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102510"},{"key":"2026091201301767000_4.3.e100526.105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00795-013-0017-0","article-title":"PPAR\u03b3 ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis","volume":"46","author":"Nozaki","year":"2013","journal-title":"Med Mol Morphol"},{"key":"2026091201301767000_4.3.e100526.106","doi-asserted-by":"crossref","unstructured":"Fan J , Tang X , Wang Q , et al . Mesenchymal stem cells alleviate experimental autoimmune cholangitis through immunosuppression and cytoprotective function mediated by galectin-9. Stem Cell Res Ther 2018;9. doi:10.1186\/s13287-018-0979-x","DOI":"10.1186\/s13287-018-0979-x"},{"key":"2026091201301767000_4.3.e100526.107","doi-asserted-by":"crossref","DOI":"10.1093\/stcltm\/szaf023","article-title":"Bone mesenchymal stem cells attenuate hepatic stellate cell activation and liver fibrosis through REDD1\/autophagy pathway","volume":"14","author":"Huang","year":"2025","journal-title":"Stem Cells Transl Med"},{"key":"2026091201301767000_4.3.e100526.108","doi-asserted-by":"crossref","unstructured":"Chen W , Zhu J , Lin F , et al . Human placenta mesenchymal stem cell-derived exosomes delay H2O2-induced aging in mouse cholangioids. Stem Cell Res Ther 2021;12:201. doi:10.1186\/s13287-021-02271-3","DOI":"10.1186\/s13287-021-02271-3"},{"key":"2026091201301767000_4.3.e100526.109","doi-asserted-by":"crossref","unstructured":"Yang Y , Zhao RC , Zhang F . Potential mesenchymal stem cell therapeutics for treating primary biliary cholangitis: advances, challenges, and perspectives. Front Cell Dev Biol 2022;10:933565. doi:10.3389\/fcell.2022.933565","DOI":"10.3389\/fcell.2022.933565"},{"key":"2026091201301767000_4.3.e100526.110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103414"},{"key":"2026091201301767000_4.3.e100526.111","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31316"},{"key":"2026091201301767000_4.3.e100526.112","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/liv.15596","article-title":"Setanaxib, a first-in-class selective NADPH oxidase 1\/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial","volume":"43","author":"Invernizzi","year":"2023","journal-title":"Liver Int"},{"key":"2026091201301767000_4.3.e100526.113","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.3.1655"},{"key":"2026091201301767000_4.3.e100526.114","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/hep.28641","article-title":"Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance","volume":"64","author":"Bae","year":"2016","journal-title":"Hepatology"},{"key":"2026091201301767000_4.3.e100526.115","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051911"},{"key":"2026091201301767000_4.3.e100526.116","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22390"},{"key":"2026091201301767000_4.3.e100526.117","doi-asserted-by":"crossref","unstructured":"Wang X , Wei Y , Yang Y , et al . Animal models of primary biliary cholangitis: status and challenges. Cell Biosci 2023;13:214. doi:10.1186\/s13578-023-01170-9","DOI":"10.1186\/s13578-023-01170-9"},{"key":"2026091201301767000_4.3.e100526.118","doi-asserted-by":"crossref","first-page":"103287","DOI":"10.1016\/j.jaut.2024.103287","article-title":"High-fat diet modulates bile acid composition and gut microbiota, affecting severe cholangitis and cirrhotic change in murine primary biliary cholangitis","volume":"148","author":"Umemura","year":"2024","journal-title":"J Autoimmun"},{"key":"2026091201301767000_4.3.e100526.119","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000110","article-title":"Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells","volume":"7","author":"Mulcahy","year":"2023","journal-title":"Hepatol Commun"},{"key":"2026091201301767000_4.3.e100526.120","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2025-100202","article-title":"New insights into liver injury and regeneration from single-cell transcriptomics","volume":"3","author":"Wen","year":"2025","journal-title":"eGastroenterology"}],"container-title":["eGastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/egastro-2026-100526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:30:37Z","timestamp":1789201837000},"score":1,"resource":{"primary":{"URL":"http:\/\/egastroenterology.bmj.com\/lookup\/doi\/10.1136\/egastro-2026-100526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":120,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9,12]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/egastro-2026-100526"],"URL":"https:\/\/doi.org\/10.1136\/egastro-2026-100526","relation":{},"ISSN":["2766-0125","2976-7296"],"issn-type":[{"value":"2766-0125","type":"print"},{"value":"2976-7296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}